Product image of Mucopront (Carbocisteine) supplied by GNH India

Mucopront

Active Ingredient:
Carbocisteine
Origin:
EU

Mucopront (Carbocisteine)

Carbocisteine, the active ingredient in Mucopront, is a mucolytic presented as an oral formulation for oral use. It reduces the thickness of mucus, facilitating clearance in patients with chronic bronchitis, chronic obstructive pulmonary disease, and respiratory infections characterized by thick sputum.

GNH India supplies Mucopront as a licensed, GDP‑compliant international pharmaceutical supplier, ensuring quality and regulatory compliance while serving hospitals, pharmacies and clinics worldwide. The company leverages a global logistics network to deliver products promptly and safely across EU and other markets.

Manufacturer / TM Owner

Bausch Health Ireland Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Carbocisteine is used as a mucolytic to improve mucus clearance in several respiratory conditions.

  • Chronic bronchitis: reduces sputum viscosity, making it easier to expectorate and decreasing cough frequency.
  • Chronic obstructive pulmonary disease (COPD): helps clear airway secretions, improves airflow and may reduce exacerbation severity.
  • Respiratory tract infections with thick mucus: facilitates removal of mucus, supporting airway patency and aiding recovery.

How It Works

  • Carbocisteine acts by cleaving disulfide bonds within mucoproteins, thereby breaking down the polymeric structure of mucus. This reduction in cross‑linking lowers sputum viscosity and elasticity, allowing ciliary action and cough to transport mucus more efficiently out of the respiratory tract. By improving mucus rheology, carbocisteine enhances mucociliary clearance and reduces the risk of airway obstruction.

Side Effects

Carbocisteine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

  • Nausea: mild stomach upset.
  • Diarrhea: loose stools.
  • Abdominal pain: discomfort in the abdomen.
  • Dizziness: transient light‑headedness.

Serious or Rare Side Effects

  • Allergic reactions: rash, itching, swelling.
  • Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
  • Hepatic dysfunction: elevated liver enzymes or jaundice.

Precautions & Warnings

When prescribing carbocisteine, clinicians should consider several precautionary measures to ensure safe use.

  • Renal impairment: adjust dose or monitor renal function in patients with reduced kidney function.
  • Hepatic disease: use cautiously in patients with liver disorders and monitor liver enzymes.
  • Concomitant antitussives: avoid combining with suppressants of cough as mucus clearance may be hindered.
  • Asthma: monitor for bronchospasm, especially in patients with reactive airway disease.
  • Pregnancy and lactation: assess risk‑benefit, as safety data are limited.
  • Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Avoid Interactions

Carbocisteine can interact with certain medicines, affecting either its efficacy or the safety profile of the co‑administered drug.

Major Interactions (Avoid)

  • Other mucolytics: combined use may increase gastrointestinal irritation.
  • Nitrofurantoin: carbocisteine may reduce its antibacterial activity.

Moderate Interactions (Monitor Closely)

  • Macrolide antibiotics (e.g., azithromycin): monitor for increased GI upset.
  • Anticoagulants (e.g., warfarin): observe INR as mucolytics can affect plasma protein binding.
  • Bronchodilators (e.g., beta‑agonists): assess for additive cough suppression.
  • Antihistamines: watch for enhanced sedation or dizziness.

Frequently Asked Questions

Mucopront contains carbocisteine, a mucolytic agent that helps thin and loosen thick mucus in the airways. It is commonly prescribed for conditions such as chronic bronchitis, chronic obstructive pulmonary disease (COPD), and respiratory infections where patients experience excessive, viscous sputum.

Carbocisteine works by breaking disulfide bonds in mucoproteins, which reduces the cross‑linking of mucus polymers. This action lowers the viscosity and elasticity of sputum, making it easier for ciliary action and coughing to clear the mucus from the respiratory tract.

The appropriate dose of Mucopront is determined by the prescribing healthcare professional based on the patient’s condition, age, and overall health. Dosage instructions are individualized and should be followed exactly as written on the prescription label.

Safety data for carbocisteine in pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits against any possible risks before prescribing Mucopront to pregnant or nursing mothers. The decision should be made on a case‑by‑case basis.

To order Mucopront, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mucopront’s active ingredient, carbocisteine, primarily reduces mucus viscosity by cleaving disulfide bonds, whereas other mucolytics such as N‑acetylcysteine act as antioxidants and may have additional mucolytic mechanisms. Carbocisteine is generally well‑tolerated and is chosen for its specific action on sputum rheology.

Mucopront should be stored at ambient temperature below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to extreme temperatures or humidity.

Mucopront is taken orally, usually in tablet or capsule form, as directed by a healthcare professional. It should be swallowed with a glass of water and can be taken with or without food, unless otherwise instructed by the prescriber.

Serious risks, though rare, include severe allergic reactions such as rash, swelling, or Stevens‑Johnson syndrome, and hepatic dysfunction manifested by elevated liver enzymes or jaundice. Patients should seek immediate medical attention if they experience any signs of a serious reaction.

Mucopront should be avoided in individuals with known hypersensitivity to carbocisteine or any excipients in the formulation. Caution is also advised for patients with severe renal or hepatic impairment, and it should not be used in conjunction with cough suppressants that may impede mucus clearance.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Carbocisteine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT